Session

Oesophagus: All about reflux, EoE and achalasia (Posters)

CONTROLLABLE DELIVERY OF CYTOPROTECTIVE CARBON MONOXIDE (CO) USING NOVEL CO-DELIVERING PRODRUGS COUNTERACTS BARRETT’S-LIKE METAPLASIA DEVELOPMENT
CONTROLLABLE DELIVERY OF CYTOPROTECTIVE CARBON MONOXIDE (CO) USING NOVEL CO-DELIVERING PRODRUGS COUNTERACTS BARRETT’S-LIKE METAPLASIA DEVELOPMENT

Oesophagus: All about reflux, EoE and achalasia (Posters)  et al.

THE LYON SCORE: A NOVEL REFLUX SCORING SYSTEM THAT PREDICTS TREATMENT OUTCOME FROM ANTI-REFLUX THERAPY
THE LYON SCORE: A NOVEL REFLUX SCORING SYSTEM THAT PREDICTS TREATMENT OUTCOME FROM ANTI-REFLUX THERAPY

Oesophagus: All about reflux, EoE and achalasia (Posters)  et al.

REFLUX HYPERSENSITIVITY VS FUNCTONAL HEARTBURN. FOCUSING ON CHARACTERISTICS OF PATIENTS WITH REFLUX HYPERSENSITIVITY ACCORDING TO SYMPTOMS PERCEPTION MARKERS WITH A SPECIAL INTEREST IN PPI RESPONSE
REFLUX HYPERSENSITIVITY VS FUNCTONAL HEARTBURN. FOCUSING ON CHARACTERISTICS OF PATIENTS WITH REFLUX HYPERSENSITIVITY ACCORDING TO SYMPTOMS PERCEPTION MARKERS WITH A SPECIAL INTEREST IN PPI RESPONSE

Oesophagus: All about reflux, EoE and achalasia (Posters)  et al.

INCIDENCE OF NON-ESOPHAGEAL EOSINOPHILIC GASTROINTESTINAL DISEASE IN SWEDEN 1990-2015
INCIDENCE OF NON-ESOPHAGEAL EOSINOPHILIC GASTROINTESTINAL DISEASE IN SWEDEN 1990-2015

Oesophagus: All about reflux, EoE and achalasia (Posters)  et al.

ANTI–IL-13 (CENDAKIMAB) ADMINISTRATION IMPROVES OESOPHAGEAL GENE EXPRESSION IN EOSINOPHILIC OESOPHAGITIS
ANTI–IL-13 (CENDAKIMAB) ADMINISTRATION IMPROVES OESOPHAGEAL GENE EXPRESSION IN EOSINOPHILIC OESOPHAGITIS

Oesophagus: All about reflux, EoE and achalasia (Posters)  et al.

UPPER ESOPHAGEAL SPHINCTER METRICS ACROSS EOSINOPHILIC ESOPHAGITIS, GASTROESOPHAGEAL REFLUX DISEASE AND FUNCTIONAL DYSPHAGIA: A PILOT STUDY
UPPER ESOPHAGEAL SPHINCTER METRICS ACROSS EOSINOPHILIC ESOPHAGITIS, GASTROESOPHAGEAL REFLUX DISEASE AND FUNCTIONAL DYSPHAGIA: A PILOT STUDY

Oesophagus: All about reflux, EoE and achalasia (Posters)  et al.

ABSENT PERISTALSIS DOES NOT INCREASE THE RISK OF DYSPHAGIA IN PATIENTS UNDERGOING ANTI-REFLUX SURGERY
ABSENT PERISTALSIS DOES NOT INCREASE THE RISK OF DYSPHAGIA IN PATIENTS UNDERGOING ANTI-REFLUX SURGERY

Oesophagus: All about reflux, EoE and achalasia (Posters)  et al.

EFFICACY OF DUPILUMAB IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS AND PRIOR USE OR PRIOR INADEQUATE RESPONSE, INTOLERANCE, OR CONTRAINDICATION TO SWALLOWED TOPICAL CORTICOSTEROIDS: RESULTS FROM PART C OF THE LIBERTY EOE TREET STUDY
EFFICACY OF DUPILUMAB IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS AND PRIOR USE OR PRIOR INADEQUATE RESPONSE, INTOLERANCE, OR CONTRAINDICATION TO SWALLOWED TOPICAL CORTICOSTEROIDS: RESULTS FROM PART C OF THE LIBERTY EOE TREET STUDY

Oesophagus: All about reflux, EoE and achalasia (Posters)  et al.

EOSINOPHILIC OESOPHAGITIS (EOE): RISK FACTORS, RELATIONSHIP WITH DISORDERS OF GUT-BRAIN INTERACTIONS (DGBI), AND MORTALITY
EOSINOPHILIC OESOPHAGITIS (EOE): RISK FACTORS, RELATIONSHIP WITH DISORDERS OF GUT-BRAIN INTERACTIONS (DGBI), AND MORTALITY

Oesophagus: All about reflux, EoE and achalasia (Posters)  et al.

EOSINOPHILIC OESOPHAGITIS (EOE): RISK FACTORS, RELATIONSHIP WITH DISORDERS OF GUT-BRAIN INTERACTIONS (DGBI), AND MORTALITY
EOSINOPHILIC OESOPHAGITIS (EOE): RISK FACTORS, RELATIONSHIP WITH DISORDERS OF GUT-BRAIN INTERACTIONS (DGBI), AND MORTALITY

CONTROLLABLE DELIVERY OF CYTOPROTECTIVE CARBON MONOXIDE (CO) USING NOVEL CO-DELIVERING PRODRUGS COUNTERACTS BARRETT’S-LIKE METAPLASIA DEVELOPMENT
CONTROLLABLE DELIVERY OF CYTOPROTECTIVE CARBON MONOXIDE (CO) USING NOVEL CO-DELIVERING PRODRUGS COUNTERACTS BARRETT’S-LIKE METAPLASIA DEVELOPMENT

INCIDENCE OF NON-ESOPHAGEAL EOSINOPHILIC GASTROINTESTINAL DISEASE IN SWEDEN 1990-2015
INCIDENCE OF NON-ESOPHAGEAL EOSINOPHILIC GASTROINTESTINAL DISEASE IN SWEDEN 1990-2015

EFFICACY OF DUPILUMAB IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS AND PRIOR USE OR PRIOR INADEQUATE RESPONSE, INTOLERANCE, OR CONTRAINDICATION TO SWALLOWED TOPICAL CORTICOSTEROIDS: RESULTS FROM PART C OF THE LIBERTY EOE TREET STUDY
EFFICACY OF DUPILUMAB IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS AND PRIOR USE OR PRIOR INADEQUATE RESPONSE, INTOLERANCE, OR CONTRAINDICATION TO SWALLOWED TOPICAL CORTICOSTEROIDS: RESULTS FROM PART C OF THE LIBERTY EOE TREET STUDY

THE LYON SCORE: A NOVEL REFLUX SCORING SYSTEM THAT PREDICTS TREATMENT OUTCOME FROM ANTI-REFLUX THERAPY
THE LYON SCORE: A NOVEL REFLUX SCORING SYSTEM THAT PREDICTS TREATMENT OUTCOME FROM ANTI-REFLUX THERAPY

REFLUX HYPERSENSITIVITY VS FUNCTONAL HEARTBURN. FOCUSING ON CHARACTERISTICS OF PATIENTS WITH REFLUX HYPERSENSITIVITY ACCORDING TO SYMPTOMS PERCEPTION MARKERS WITH A SPECIAL INTEREST IN PPI RESPONSE
REFLUX HYPERSENSITIVITY VS FUNCTONAL HEARTBURN. FOCUSING ON CHARACTERISTICS OF PATIENTS WITH REFLUX HYPERSENSITIVITY ACCORDING TO SYMPTOMS PERCEPTION MARKERS WITH A SPECIAL INTEREST IN PPI RESPONSE

ANTI–IL-13 (CENDAKIMAB) ADMINISTRATION IMPROVES OESOPHAGEAL GENE EXPRESSION IN EOSINOPHILIC OESOPHAGITIS
ANTI–IL-13 (CENDAKIMAB) ADMINISTRATION IMPROVES OESOPHAGEAL GENE EXPRESSION IN EOSINOPHILIC OESOPHAGITIS

UPPER ESOPHAGEAL SPHINCTER METRICS ACROSS EOSINOPHILIC ESOPHAGITIS, GASTROESOPHAGEAL REFLUX DISEASE AND FUNCTIONAL DYSPHAGIA: A PILOT STUDY
UPPER ESOPHAGEAL SPHINCTER METRICS ACROSS EOSINOPHILIC ESOPHAGITIS, GASTROESOPHAGEAL REFLUX DISEASE AND FUNCTIONAL DYSPHAGIA: A PILOT STUDY

ABSENT PERISTALSIS DOES NOT INCREASE THE RISK OF DYSPHAGIA IN PATIENTS UNDERGOING ANTI-REFLUX SURGERY
ABSENT PERISTALSIS DOES NOT INCREASE THE RISK OF DYSPHAGIA IN PATIENTS UNDERGOING ANTI-REFLUX SURGERY

Item 1 - 18 / 18
1